Strongbridge Biopharma

Discussion in 'Biotech Startups' started by anonymous, Oct 23, 2017 at 1:22 AM.

  1. anonymous

    anonymous Guest

    Does anyone know what they Strongbridge is offering for a vehicle program?
     

  2. anonymous

    anonymous Guest

    A prison van thanks to their predatory pricing.
     
  3. anonymous

    anonymous Guest

    Just read about this company. Minimal sales and small prospects. Not sure how they afford a fleet.
     
  4. anonymous

    anonymous Guest

    Endo expansion happening?
     
  5. anonymous

    anonymous Guest

    They give $1,000 a month car allowance,
    their Neuro division is expanding to
    sell the $200,000 per yr drug to
    Treat PPP
     
  6. anonymous

    anonymous Guest

    Just read about them. Interesting idea to overpriced low-volume drugs. Might work for a time but seems an old idea that is going to get them into trouble like Turing and Valeant. They seem to have a program for another drug that is taking forever to finish and also looks like a modified generic.
     
  7. anonymous

    anonymous Guest

    The endo group will be selling a diagnostic product for AGHD. Small division.
     
  8. anonymous

    anonymous Guest

    No money in diagnostics, especially for rare diseases and a “one and done” test. This seems to be a stupid company. They are going need to charge lots to make any money. Likely Strongbridge were able to buy these products on the cheap because the companies that sold to Strongbridge had too many scruples to victimize patients.
     
  9. anonymous

    anonymous Guest

    The diagnostic test for AGHD is legit. The above poster is uninformed. The pipeline is neuro-endocrine. The endocrine AGHD test is simply the entry into the endocrinology community. It is not expected to be a huge seller, but is by far a better alternative to ITT currently used.
     
  10. anonymous

    anonymous Guest

    Pay is great, bonus is decent. Car allowance. Sounds good to me. Oh yeah, lots of stock options.
     
  11. anonymous

    anonymous Guest

    The stock market seems to think there isn’t much value in overcharging for old drugs. Just see what CNN did to MNK. This company is a scandal waiting to happen.
     
  12. anonymous

    anonymous Guest

    The stock will be low until they launch the cushings disease drug...that’s when the company will begin to grow.
     
  13. anonymous

    anonymous Guest

    Their Cushing study is taking forever and open label I read. Nothing to promote with, and it’s an old drug.
     
  14. anonymous

    anonymous Guest

    Can’t imagine working at SB, especially selling an old drug at a jacked up price to neurologists.

    And no one’s going to buy this POS.
     
  15. anonymous

    anonymous Guest

    high risk, high reward...
     
  16. anonymous

    anonymous Guest

    Hi risk for sales people when the DOJ steps in for price gouging. Like many who looked at roles at SB, it seems a value nothingburger.
     
  17. anonymous

    anonymous Guest

    Was recruited by DB himself to join him at SB.

    Wish these people the best, but no company in their right mind will acqiure this pig.
     
  18. anonymous

    anonymous Guest


    DB himself belongs back in big Pharma.
     
  19. anonymous

    anonymous Guest

    This company is toast. FDA cracking down on profiteers exploiting single-source generic drugs. Only thing saving them so far is that they are so insignicant nobody is paying attention.
     
  20. anonymous

    anonymous Guest

    Actually they’ve already gotten a letter from a senator about predatory pricing. But who cares if the pay is good?